Global RNAi Technologies Markets to 2027 - Rise in the Number of Genetic & Metabolic Disorders - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 27, 2018--The “Global RNAi Technologies Market Analysis & Trends - Industry Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.
The Global RNAi Technologies Market is poised to grow strong during the forecast period 2017 to 2027.
Some of the prominent trends that the market is witnessing include rise in number of genetic and metabolic disorders, improvement in synthetic delivery carriers and chemical modifications to RNA, recent technological developments in RNAi technologies and growth opportunities/investment opportunities.
This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2015, 2016 revenue estimations are presented for 2017 and forecasts from 2018 till 2027.
The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.
The study presents detailed market analysis with inputs derived from industry professionals across the value chain. A special focus has been made on 23 countries such as U.S., Canada, Mexico, U.K., Germany, Spain, France, Italy, China, Brazil, Saudi Arabia, South Africa, etc.
Report HighlightsThe report provides a detailed analysis on current and future market trends to identify the investment opportunities Market forecasts till 2027, using estimated market values as the base numbers Key market trends across the business segments, Regions and Countries Key developments and strategies observed in the market Market Dynamics such as Drivers, Restraints, Opportunities and other trends In-depth company profiles of key players and upcoming prominent players Growth prospects among the emerging nations through 2027 Market opportunities and recommendations for new investments
Key Topics Covered
1 Market Outline
1.1 Research Methodology
1.1.1 Research Approach & Sources
1.2 Market Trends
1.3 Regulatory Factors
1.4 Application Analysis
1.5 Strategic Benchmarking
1.6 Opportunity Analysis
2 Executive Summary
3 Market Overview
3.1 Current Trends
3.1.1 Rise in Number of Genetic & Metabolic Disorders
3.1.2 Improvement in Synthetic Delivery Carriers and Chemical Modifications to RNA
3.1.3 Recent Technological Developments in RNAi Technologies
3.1.4 Growth Opportunities/Investment Opportunities
3.4 Industry Attractiveness
3.4.1 Bargaining power of suppliers
3.4.2 Bargaining power of buyers
3.4.3 Threat of substitutes
3.4.4 Threat of new entrants
3.4.5 Competitive rivalry
4 RNAi Technologies Market, By Therapeutics
4.1 Ocular disorders
4.2 Respiratory disorders
4.5 Liver diseases
4.7 Metabolic disorders
4.9 Heart ailment
4.10 Autoimmune hepatitis
5 RNAi Technologies Market, By Application
5.1 Drug discovery
5.2 Medical research
5.2.1 Functional genomics
5.2.2 Specifically metabolism
6 RNAi Technologies Market, By Type
6.1 Micro RNAi
6.2 Small interfering RNAi
7 RNAi Technologies Market, By Geography
7.1 North America
7.2.6 Rest of Europe
7.3 Asia Pacific
7.3.5 New Zealand
7.3.6 Rest of Asia Pacific
7.4 Middle East
7.4.1 Saudi Arabia
7.4.3 Rest of Middle East
7.5 Latin America
7.5.3 Rest of Latin America
7.6 Rest of the World (RoW)
7.6.1 South Africa
8 Key Player Activities
8.1 Acquisitions & Mergers
8.2 Agreements, Partnerships, Collaborations and Joint Ventures
8.3 Product Launch & Expansions
8.4 Other Activities
9 Leading Companies
9.1 Thermo Fisher Scientific Inc.
9.2 Syngenta International AG
9.3 Monsanto Co.
9.4 General Electric Co.
9.5 F. Hoffmann-La Roche AG
9.6 Benitec Biopharma Ltd.
9.7 Alnylam Pharmaceuticals
9.8 Ionis Pharmaceuticals
9.9 RXI Pharmaceuticals
9.10 Quark Pharmaceuticals Inc.
9.11 Filmtec Corporation
9.12 Rosetta Genomics Ltd.
9.14 Nitto Denko Corp.
9.15 Biogen Idec Inc.
For more information about this report visit https://www.researchandmarkets.com/research/2vm8s7/global_rnai?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181127005420/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH GENETICS
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 11/27/2018 06:24 AM/DISC: 11/27/2018 06:24 AM